P. Nanni

Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
202430 citationsauthor #9
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay.
20241 citationsauthor #7
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
202334 citationsauthor #8
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
20227 citationsauthor #16
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
202113 citationsauthor #5
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
202110 citationsauthor #23
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
202118 citationsauthor #13
IFN-γ and CD38 in Hyperprogressive Cancer Development
202120 citationsauthor #7
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
201910 citationsauthor #9
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
201967 citationsauthor #1
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
201912 citationsauthor #2
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model
201920 citationsauthor #6
’ s response to reviews Title : Immune targeting of autocrine IGF 2 hampers rhabdomyosarcoma growth and metastasis
20190 citationsauthor #2
Abstract 716: A novel virus-like particle vaccine presenting HER-2 extracellular domain elicits strong immune responses against mammary carcinoma
20180 citationsauthor #18
Abstract 2079: Collection of patient-derived xenografts (PDX) to study the biology and therapy of bone sarcomas
20180 citationsauthor #9
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
201835 citationsauthor #13
Cancer immunoprevention: from mice to early clinical trials
201810 citationsauthor #4
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
20187 citationsauthor #1
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
201872 citationsauthor #8
HER2 cancer vaccine optimization by combining Drosophila S2 insect cell manufacturing with a novel VLP-display technology
20180 citationsauthor #16
Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
201837 citationsauthor #8
Virus-like particle display of HER2 induces potent anti-cancer responses
201898 citationsauthor #18
Abstract 216: Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts
20181 citationsauthor #17
HER 2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset , vasculature and therapeutic response
20177 citationsauthor #24
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.
201714 citationsauthor #20
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
20178 citationsauthor #20
HMGA 1 / E 2 F 1 AXIS AND NFKB PATHWAYS REGULATE LIPOSARCOMA PROGRESSION AND TRABECTEDIN RESISTANCE
20170 citationsauthor #13
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
201648 citationsauthor #12
Role of d16HER2 in HER2-positive breast cancer stem cells
20161 citationsauthor #5
Abstract 1200: HER-2 isoform interaction in mammary carcinoma onset and progression
20160 citationsauthor #14
Abstract 3826: Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast cancers
20160 citationsauthor #9
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
201569 citationsauthor #11
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
20151 citationsauthor #2
The Promise of Preventive Cancer Vaccines
201538 citationsauthor #3
Abstract 2314: d16HER2 splice variant regulates the activity of HER2-positive breast cancer-initiating cells
20150 citationsauthor #12
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
201512 citationsauthor #2
662: HER2 isoforms in mammary carcinogenesis and targeted therapy susceptibility
20140 citationsauthor #10
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers
201434 citationsauthor #11
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
201477 citationsauthor #16
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
20141 citationsauthor #16
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells
201416 citationsauthor #10
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells
20140 citationsauthor #10
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
201443 citationsauthor #16
Abstract 2774: Coexpression of Delta16 isoform and full-length HER-2 in F1 hybrid transgenic mice: effects on tumor growth and malignancy
20140 citationsauthor #15
Abstract 1820: Dynamics of HER-2 loss in mammary carcinoma of human HER-2 trangenic mice
20140 citationsauthor #1
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers
20141 citationsauthor #11
Abstract 2637: Role of d16HER2 splice variant in HER2-positive breast cancer
20140 citationsauthor #11
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment.
201499 citationsauthor #8
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas
201412 citationsauthor #13
Preclinical HER-2 Vaccines: From Rodent to Human HER-2
20137 citationsauthor #3
Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
201353 citationsauthor #1
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells
20131 citationsauthor #7
Abstract 1409: Genetic ablation of lymphoma development inp53 knockout mice reveals a novel model of osteosarcoma and hemangiosarcoma.
20130 citationsauthor #9
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells
201391 citationsauthor #7
Preclinical vaccines against mammary carcinoma
201313 citationsauthor #4
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
201312 citationsauthor #13
with Conventional Adjuvants -Interferon Gene or Admixed γ Colony-stimulating Factor, and , Granulocyte-Macrophage α Necrosis Factor Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Nonreplicating Murine Mammary Adenocarcinoma Cells Immunizing and Curative Potential of Replicating a
20130 citationsauthor #3
Abstract 1403: Multiorogan metastasis of human HER-2+ breast cancer in immunodeficient mice
20120 citationsauthor #10
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
201210 citationsauthor #16
Abstract 2715: Treatment of disseminated HER-2 carcinomas with a HER-2-retargeted oncolytic herpes virus
20120 citationsauthor #12
The molecular basis of herpesviruses as oncolytic agents.
20125 citationsauthor #3
HERPESVIRUSES AS ONCOLYTIC AGENTS
20121 citationsauthor #5
Preclinical and Preliminary Clinical Activity of NVP-BKM120, an Oral Pan-Class I PI3K Inhibitor, in the Brain
201215 citationsauthor #6
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor
201289 citationsauthor #1
Rethinking herpes simplex virus: the way to oncolytic agents
201177 citationsauthor #4
Vaccines and other immunological approaches for cancer immunoprevention.
201142 citationsauthor #7
2011: the immune hallmarks of cancer
2011359 citationsauthor #3
A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function.
201196 citationsauthor #8
Methods of treating bone cancer
20110 citationsauthor #2
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines.
20116 citationsauthor #10
Cancer Metastasis: Immunotherapy
20110 citationsauthor #3
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER‐2/neu oncogene‐driven animal model system
20110 citationsauthor #11
Modeling the competition between lung metastases and the immune system using agents
201062 citationsauthor #5
In silico modeling and in vivo efficacy of cancer-preventive vaccinations.
201017 citationsauthor #12
Immunoprevention and Immunotherapy of Mammary Carcinoma
20105 citationsauthor #5
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER‐2/neu oncogene‐driven animal model system
201011 citationsauthor #11
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
201032 citationsauthor #1
Cancer esearch rated Systems and Technologies : Mathematical Oncology ilico Modeling and In vivo Efficacy of R cer-Preventive Vaccinations
201068 citationsauthor #12
A Multi-DNA Preventive Vaccine for p53/Neu-Driven Cancer Syndrome
200913 citationsauthor #17
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
20093 citationsauthor #13
Oncolytic herpes virus retargeted to HER-2
20094 citationsauthor #5
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells
200993 citationsauthor #7
Molecular and cellular biology of rhabdomyosarcoma.
200993 citationsauthor #5
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4
200922 citationsauthor #1
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis
200810 citationsauthor #7
Liver metastatic growth of human tumor cells in Rag2-/-;γc-/- mice
20070 citationsauthor #9
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells.
20078 citationsauthor #6
Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma
2007144 citationsauthor #3
Antimetastatic activity of a preventive cancer vaccine.
200746 citationsauthor #1
Antimetastatic activity of a preventive cancer vaccine (Cancer Research (2007) 67, (11037-11044))
20078 citationsauthor #1
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis
20073 citationsauthor #13
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity
200770 citationsauthor #9
Vaccines for tumour prevention
2006328 citationsauthor #3
Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role.
20063 citationsauthor #10
Insulin‐like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma
200654 citationsauthor #6
CD99 acts as an oncosuppressor in osteosarcoma.
200673 citationsauthor #4
CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine1
2006100 citationsauthor #9
Late abstracts 186–187
20050 citationsauthor #29
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
200553 citationsauthor #12
New target antigens for cancer immunoprevention.
200516 citationsauthor #5

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT